The use of intraperitoneal chemotherapy.
The i.p. route of drug administration has a clearly defined theoretical basis. Detailed information is now available on the i.p. pharmacology and toxicity of most drugs active in ovarian cancer. In addition, there are clearly defined clinical situations in which use of this form of therapy would be rational. The major remaining task is to conduct well-designed clinical trials to determine the actual value of this approach.
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use; D001202:Ascitic Fluid / Q000378:metabolism; D004341:Drug Evaluation; D006801:Humans; D007274:Injections, Intraperitoneal; D009369:Neoplasms / Q000188:drug therapy / Q000378:metabolism; D014018:Tissue Distribution
D000970:Antineoplastic Agents